US6936694B1
(en)
|
1982-05-06 |
2005-08-30 |
Intermune, Inc. |
Manufacture and expression of large structural genes
|
EP0401384B1
(en)
*
|
1988-12-22 |
1996-03-13 |
Kirin-Amgen, Inc. |
Chemically modified granulocyte colony stimulating factor
|
US20020177688A1
(en)
*
|
1988-12-22 |
2002-11-28 |
Kirin-Amgen, Inc., |
Chemically-modified G-CSF
|
US5906816A
(en)
*
|
1995-03-16 |
1999-05-25 |
University Of Florida |
Method for treatment of autoimmune diseases
|
US6372206B1
(en)
|
1989-03-02 |
2002-04-16 |
University Of Florida |
Orally-administered interferon-TAU compositions and methods
|
US5372808A
(en)
†
|
1990-10-17 |
1994-12-13 |
Amgen Inc. |
Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
|
EP0625991B1
(en)
*
|
1992-02-10 |
1999-04-28 |
Interferon Sciences, Inc. |
Improved alpha interferon composition and method for its production from human peripheral blood leukocytes
|
US5676942A
(en)
*
|
1992-02-10 |
1997-10-14 |
Interferon Sciences, Inc. |
Composition containing human alpha interferon species proteins and method for use thereof
|
CA2164811A1
(en)
*
|
1993-06-11 |
1994-12-22 |
Sidney Pestka |
Super proteins including interferons and interleukins
|
US6001589A
(en)
*
|
1993-06-11 |
1999-12-14 |
Pbl Biomedical Laboratories, Inc. |
Method of identifying proteins modified by disease states related thereto
|
AU1299295A
(en)
*
|
1993-12-02 |
1995-06-19 |
President And Fellows Of Harvard College |
Improved efficacy of alpha-helical cytokines
|
DE69534676T2
(de)
*
|
1994-02-08 |
2006-08-17 |
Amgen Inc., Thousand Oaks |
Orale Verabreichung von chemisch modifizierten Proteinen
|
US20030053982A1
(en)
*
|
1994-09-26 |
2003-03-20 |
Kinstler Olaf B. |
N-terminally chemically modified protein compositions and methods
|
US5824784A
(en)
*
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
IL116730A0
(en)
*
|
1995-01-13 |
1996-05-14 |
Amgen Inc |
Chemically modified interferon
|
US6214535B1
(en)
*
|
1995-08-30 |
2001-04-10 |
Toray Industries, Inc. |
Method for testing cardiac myocarditis or cardiomyopathy
|
US5908621A
(en)
*
|
1995-11-02 |
1999-06-01 |
Schering Corporation |
Polyethylene glycol modified interferon therapy
|
CA2329474C
(en)
|
1995-11-02 |
2002-02-26 |
Schering Corporation |
Continuous low-dose cytokine infusion therapy
|
US5739313A
(en)
*
|
1995-11-13 |
1998-04-14 |
Regents Of The University Of Minnesota |
Radionuclide labeling of vitamin B12 and coenzymes thereof
|
US20030026779A1
(en)
*
|
1999-10-15 |
2003-02-06 |
Liming Yu |
Treatment of tumors and viral infections with a hybrid conjugate of interferon and an immunoglobulin Fc
|
US5980884A
(en)
*
|
1996-02-05 |
1999-11-09 |
Amgen, Inc. |
Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
|
CN1151841C
(zh)
*
|
1996-05-09 |
2004-06-02 |
太平洋制药控股公司 |
干扰素在制备刺激防御机制或免疫反应的药物中的应用
|
US5831062A
(en)
*
|
1996-05-09 |
1998-11-03 |
Amgen Inc. |
Use of the human interferon consensus gene for gene therapy
|
AUPN976596A0
(en)
*
|
1996-05-09 |
1996-05-30 |
Pharma Pacific Pty Ltd |
Stimulation of host defence mechanisms
|
US20030190307A1
(en)
*
|
1996-12-24 |
2003-10-09 |
Biogen, Inc. |
Stable liquid interferon formulations
|
US6013253A
(en)
*
|
1997-08-15 |
2000-01-11 |
Amgen, Inc. |
Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
|
US6017876A
(en)
|
1997-08-15 |
2000-01-25 |
Amgen Inc. |
Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
|
US6541033B1
(en)
|
1998-06-30 |
2003-04-01 |
Amgen Inc. |
Thermosensitive biodegradable hydrogels for sustained delivery of leptin
|
WO2000018427A1
(en)
*
|
1998-09-29 |
2000-04-06 |
Fleischmann W Robert |
Methods of treating diseased cells
|
US6420339B1
(en)
|
1998-10-14 |
2002-07-16 |
Amgen Inc. |
Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
|
US6245740B1
(en)
|
1998-12-23 |
2001-06-12 |
Amgen Inc. |
Polyol:oil suspensions for the sustained release of proteins
|
US6451346B1
(en)
*
|
1998-12-23 |
2002-09-17 |
Amgen Inc |
Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
|
RU2140285C1
(ru)
|
1999-01-25 |
1999-10-27 |
Гапонюк Петр Яковлевич |
Противовирусное средство - капли в нос "гриппферон"
|
DK1157037T3
(da)
*
|
1999-01-29 |
2003-11-24 |
Hoffmann La Roche |
GCSF-konjugater
|
US6806363B1
(en)
|
1999-04-16 |
2004-10-19 |
Mayo Foundation For Medical Education & Research |
Cobalamin conjugates useful as antitumor agents
|
US8106098B2
(en)
*
|
1999-08-09 |
2012-01-31 |
The General Hospital Corporation |
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
|
US7591995B2
(en)
*
|
1999-10-15 |
2009-09-22 |
Mayo Foundation For Medical Education And Research |
Cobalamin conjugates useful as imaging and therapeutic agents
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
CZ301182B6
(cs)
|
2000-05-26 |
2009-12-02 |
Idenix (Cayman) Limited |
Použití nukleosidových derivátu pro výrobu farmaceutických prostredku pro lécení infekcí vyvolaných flaviviry a pestiviry
|
US20030219405A1
(en)
*
|
2002-01-16 |
2003-11-27 |
Yoshihiro Sokawa |
Oral administration of interferon-tau
|
US7105154B2
(en)
*
|
2000-07-19 |
2006-09-12 |
Pepgen Corporation |
Method of treatment using interferon-tau
|
EP1334114A2
(en)
|
2000-10-25 |
2003-08-13 |
Mayo Foundation For Medical Education And Research |
Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
|
US6878364B2
(en)
*
|
2000-12-01 |
2005-04-12 |
Cornell Research Foundation, Inc. |
Animal model for flaviviridae infection
|
US20060035327A1
(en)
*
|
2001-02-28 |
2006-02-16 |
Guangwen Wei |
Recombinant super-compound interferon and uses thereof
|
US8551469B2
(en)
*
|
2001-02-28 |
2013-10-08 |
Superlab Far East Limited |
Treatment of tumors and viral diseases with recombinant interferon alpha
|
CN1245215C
(zh)
*
|
2001-02-28 |
2006-03-15 |
四川省生物工程研究中心 |
重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
|
US20050079579A1
(en)
*
|
2001-02-28 |
2005-04-14 |
Guangwen Wei |
Uses of spatial configuration to modulate protein function
|
US20030104996A1
(en)
*
|
2001-08-30 |
2003-06-05 |
Tiansheng Li |
L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
|
HUP0401659A3
(en)
*
|
2001-09-28 |
2005-02-28 |
Intermune Inc Brisbane |
Method for treating hepatitis c virus infection in treatment failure patients
|
PL369129A1
(en)
*
|
2001-09-28 |
2005-04-18 |
Intermune, Inc. |
Method for treating hepatitis c virus infection in treatment failure patients
|
US20030144198A1
(en)
*
|
2001-09-28 |
2003-07-31 |
Collins Douglas A. |
Coadministration of transport protein with conjugated cobalamin to deliver agents
|
AU2002330154A1
(en)
*
|
2001-09-28 |
2003-04-07 |
Centre National De La Recherche Scientifique |
Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
|
CA2460690A1
(en)
*
|
2001-10-05 |
2003-04-17 |
Intermune, Inc. |
Method of treating hepatitis virus infection with a multiphasic interferon delivery profile
|
WO2003049760A1
(en)
*
|
2001-12-07 |
2003-06-19 |
Intermune, Inc. |
Compositions and method for treating hepatitis virus infection
|
US20040063912A1
(en)
*
|
2002-03-15 |
2004-04-01 |
The Brigham And Women's Hospital, Inc. |
Central airway administration for systemic delivery of therapeutics
|
US20030191056A1
(en)
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
ES2469569T3
(es)
|
2002-06-28 |
2014-06-18 |
Idenix Pharmaceuticals, Inc. |
Prof�rmacos de nucle�sidos modificados en 2' y 3' para el tratamiento de infecciones de Flaviviridae
|
US7608600B2
(en)
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
AU2003248748A1
(en)
|
2002-06-28 |
2004-01-19 |
Idenix (Cayman) Limited |
2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
|
NZ537662A
(en)
|
2002-06-28 |
2007-10-26 |
Idenix Cayman Ltd |
2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
|
GB0215293D0
(en)
*
|
2002-07-03 |
2002-08-14 |
Rega Foundation |
Viral inhibitors
|
HUE033832T2
(en)
|
2002-11-15 |
2018-01-29 |
Idenix Pharmaceuticals Llc |
2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
|
US7314613B2
(en)
|
2002-11-18 |
2008-01-01 |
Maxygen, Inc. |
Interferon-alpha polypeptides and conjugates
|
JP5116972B2
(ja)
|
2002-12-12 |
2013-01-09 |
イデニクス(ケイマン)リミテツド |
2’−分枝ヌクレオシドの製造方法
|
WO2005013917A2
(en)
*
|
2003-02-28 |
2005-02-17 |
Intermune, Inc. |
Combination therapy for treating alphavirus infection and liver fibrosis
|
US20070077225A1
(en)
*
|
2003-02-28 |
2007-04-05 |
Blatt Lawrence M |
Continuous delivery methods for treating hepatitis virus infection
|
EP3521297B1
(en)
|
2003-05-30 |
2021-12-22 |
Gilead Pharmasset LLC |
Modified fluorinated nucleoside analogues
|
EP1658302B1
(en)
*
|
2003-07-25 |
2010-08-25 |
IDENIX Pharmaceuticals, Inc. |
Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
|
CN102294020A
(zh)
*
|
2003-08-28 |
2011-12-28 |
辉阳科技美国公司 |
空间构象改变的干扰素及其应用
|
US7585647B2
(en)
*
|
2003-08-28 |
2009-09-08 |
Guangwen Wei |
Nucleic acid encoding recombinant interferon
|
CA2535902A1
(en)
|
2003-08-28 |
2005-03-10 |
Huiyangtech (Usa), Inc. |
Uses of spatial configuration to modulate protein function
|
MXPA06003963A
(es)
|
2003-10-14 |
2006-08-25 |
Intermune Inc |
Acidos carboxilicos macrociclicos y acilsulfonamidas como inhibidores de replicacion del hcv.
|
SI2161273T1
(sl)
*
|
2003-12-22 |
2015-10-30 |
K.U.Leuven Research & Development |
Imidazo(4,5-c)piridin spojine in postopki protivirusnega zdravljenja
|
US20060003008A1
(en)
|
2003-12-30 |
2006-01-05 |
Gibson John W |
Polymeric devices for controlled release of active agents
|
WO2005107742A1
(en)
|
2004-05-05 |
2005-11-17 |
Yale University |
Novel antiviral helioxanthin analogs
|
CN101115769A
(zh)
|
2004-05-19 |
2008-01-30 |
马克西根公司 |
干扰素-α多肽和偶联物
|
CN101023094B
(zh)
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
RU2433124C2
(ru)
|
2004-09-14 |
2011-11-10 |
Фармассет, Инк. |
Способ получения 2'-фтор-2'-алкилзамещенных или других замещенных рибофуранозилпиримидинов и пуринов и их производных
|
EP1679065A1
(en)
|
2005-01-07 |
2006-07-12 |
OctoPlus Sciences B.V. |
Controlled release compositions for interferon based on PEGT/PBT block copolymers
|
WO2006134497A2
(en)
|
2005-03-09 |
2006-12-21 |
Guangwen Wei |
Uses of recombinant super-compound interferons
|
JP4516863B2
(ja)
*
|
2005-03-11 |
2010-08-04 |
株式会社ケンウッド |
音声合成装置、音声合成方法及びプログラム
|
MX2007014524A
(es)
|
2005-05-18 |
2008-02-07 |
Maxygen Inc |
Polipeptidos desarrollados de interferon-alfa.
|
WO2007015824A2
(en)
|
2005-07-25 |
2007-02-08 |
Intermune, Inc. |
Novel macrocyclic inhibitors of hepatitis c virus replication
|
WO2007044893A2
(en)
|
2005-10-11 |
2007-04-19 |
Intermune, Inc. |
Compounds and methods for inhibiting hepatitis c viral replication
|
US7781576B2
(en)
|
2005-12-23 |
2010-08-24 |
Idenix Pharmaceuticals, Inc. |
Process for preparing a synthetic intermediate for preparation of branched nucleosides
|
WO2007126950A1
(en)
*
|
2006-03-31 |
2007-11-08 |
Schering Corporation |
Parenteral low dose type 1 interferons for bladder cancer
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
CN101525381B
(zh)
*
|
2008-03-04 |
2012-04-18 |
北京百川飞虹生物科技有限公司 |
一种重组复合干扰素及其表达载体的构建和表达
|
TW200946541A
(en)
*
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
KR20110104074A
(ko)
|
2008-12-23 |
2011-09-21 |
파마셋 인코포레이티드 |
퓨린 뉴클레오시드의 합성
|
SG172359A1
(en)
|
2008-12-23 |
2011-07-28 |
Pharmasset Inc |
Nucleoside phosphoramidates
|
CL2009002208A1
(es)
*
|
2008-12-23 |
2010-10-29 |
Gilead Pharmasset Llc |
Un compuesto (2s)-2-((((2r,3r,4r,5r)-5-(2-amino-6-etoxi-9h-purin-9-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(hidroxi)fosforilamino)propanoico, inhibidores de la replicacion de arn viral; composicion farmaceutica; y su uso en el tratamiento de infeccion por hepatitis c, virus del nilo occidental, entre otras.
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
TWI583692B
(zh)
|
2009-05-20 |
2017-05-21 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
EP2440251A4
(en)
*
|
2009-06-09 |
2013-01-16 |
Defyrus Inc |
INTERFERON ADMINISTRATION FOR PROPHYLAXIS AGAINST PATHOGEN INFECTION OR TREATMENT OF PATHOGEN INFECTION
|
WO2011014882A1
(en)
|
2009-07-31 |
2011-02-03 |
Medtronic, Inc. |
CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
|
CN102101886A
(zh)
|
2009-12-18 |
2011-06-22 |
四川辉阳生命工程股份有限公司 |
构象改变的重组干扰素晶体、其三维结构及应用
|
KR101715981B1
(ko)
|
2010-03-31 |
2017-03-13 |
길리애드 파마셋 엘엘씨 |
뉴클레오사이드 포스포르아미데이트
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
WO2011159930A2
(en)
|
2010-06-16 |
2011-12-22 |
Medtronic, Inc. |
Damping systems for stabilizing medications in drug delivery devices
|
EA032917B1
(ru)
|
2010-09-28 |
2019-08-30 |
Амилин Фармасьютикалс, Ллк |
Сконструированные полипептиды, характеризующиеся увеличенной продолжительностью действия
|
AR084044A1
(es)
|
2010-11-30 |
2013-04-17 |
Pharmasset Inc |
Compuestos 2’-espiro-nucleosidos
|
BRPI1107312B1
(pt)
*
|
2011-11-25 |
2021-09-08 |
Universidade Federal De Santa Catarina |
Composto de acil-hidrazona
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
US8809354B2
(en)
|
2011-12-31 |
2014-08-19 |
Sheikh Riazuddin |
3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
|
TWI718086B
(zh)
*
|
2013-01-07 |
2021-02-11 |
英屬維爾京群島商遠東超級實驗室有限公司 |
通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
|
PL3650014T3
(pl)
|
2013-08-27 |
2022-01-31 |
Gilead Pharmasset Llc |
Preparat złożony dwóch związków przeciwwirusowych
|